Transcriptional Activity and Stability of CD39+CD103+CD8+T Cells in Human High-Grade Endometrial Cancer

Workel, Hagma H; van Rooij, Nienke; Plat, Annechien; Spierings, Diana C J; Fehrmann, Rudolf S N; Nijman, Hans W; de Bruyn, Marco

Published in:
International Journal of Molecular Sciences

DOI:
10.3390/ijms21113770

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2020

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Workel, H. H., van Rooij, N., Plat, A., Spierings, D. C. J., Fehrmann, R. S. N., Nijman, H. W., & de Bruyn, M. (2020). Transcriptional Activity and Stability of CD39+CD103+CD8+T Cells in Human High-Grade Endometrial Cancer. International Journal of Molecular Sciences, 21(11), 3770. https://doi.org/10.3390/ijms21113770

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Transcriptional Activity and Stability of CD39+CD103+CD8+ T Cells in Human High-Grade Endometrial Cancer

Hagma H. Workel 1, Nienke van Rooij 1, Annechien Plat 1, Diana C.J. Spierings 2,†, Rudolf S. N. Fehrmann 3, Hans W. Nijman 1,† and Marco de Bruyn 1,*,†

1 Department of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; h.h.workel@umcg.nl (H.H.W.); n.van.rooij@umcg.nl (N.v.R.); a.plat@umcg.nl (A.P.); h.w.nijman@umcg.nl (H.W.N.)
2 European Research Institute for the Biology of Ageing, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; d.c.j.spierings@umcg.nl
3 Department of Medical Oncology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands; r.s.n.fehrmann@umcg.nl
* Correspondence: m.de.bruyn@umcg.nl; Tel.: +31-(0)50-3613174; Fax: +31-(0)50-3611806
† These authors contributed equally to this work.

Received: 29 April 2020; Accepted: 22 May 2020; Published: 27 May 2020

Abstract: Tumor-infiltrating CD8+ T cells (TIL) are of the utmost importance in anti-tumor immunity. CD103 defines tumor-resident memory T cells (T RM cells) associated with improved survival and response to immune checkpoint blockade (ICB) across human tumors. Co-expression of CD39 and CD103 marks tumor-specific T RM with enhanced cytolytic potential, suggesting that CD39+CD103+ T RM could be a suitable biomarker for immunotherapy. However, little is known about the transcriptional activity of T RM cells in situ. We analyzed CD39+CD103+ T RM cells sorted from human high-grade endometrial cancers (n = 3) using mRNA sequencing. Cells remained untreated or were incubated with PMA/ ionomycin (activation), actinomycin D (a platinum-like chemotherapeutic that inhibits transcription), or a combination of the two. Resting CD39+CD103+ T RM cells were transcriptionally active and expressed a characteristic T RM signature. Activated CD39+CD103+ T RM cells differentially expressed PLEK, TWNK, and FOS, and cytokine genes IFNG, TNF, IL2, CSF2 (GM-CSF), and IL21. Findings were confirmed using qPCR and cytokine production was validated by flow cytometry of cytokytic TIL. We studied transcript stability and found that PMA-responsive genes and mitochondrial genes were particularly stable. In conclusion, CD39+CD103+ T RM cells sorted from human high-grade endometrial cancers (n = 3) using mRNA sequencing. Cells remained untreated or were incubated with PMA/ ionomycin (activation), actinomycin D (a platinum-like chemotherapeutic that inhibits transcription), or a combination of the two. Resting CD39+CD103+ T RM cells were transcriptionally active and expressed a characteristic T RM signature. Activated CD39+CD103+ T RM cells differentially expressed PLEK, TWNK, and FOS, and cytokine genes IFNG, TNF, IL2, CSF2 (GM-CSF), and IL21. Findings were confirmed using qPCR and cytokine production was validated by flow cytometry of cytokytic TIL. We studied transcript stability and found that PMA-responsive genes and mitochondrial genes were particularly stable. In conclusion, CD39+CD103+ T RM cells are transcriptionally active T RM cells with a polyfunctional, reactivation-responsive repertoire. Secondly, we hypothesize that differential regulation of transcript stability potentiates rapid responses upon T RM reactivation in tumors.

Keywords: tissue-resident memory cell; endometrial cancer; CD103; CD39; transcript stability; cytokinesis; IL-21

1. Introduction

The influence of tumor-infiltrating lymphocytes (TIL) on cancer prognosis is widely recognized, and TIL are studied in a wide variety of solid tumors. The composition of the immune infiltrate is of the utmost importance, as the immune architecture mainly determines whether the balance tips towards an anti-tumor or pro-tumor immune response [1]. CD103, the αE subunit of integrin αEβ7, defines intra-epithelial resident memory T cells (T RM cells) with increased cytolytic potential, improved immune synapse formation, and increased tumor antigen sensitivity [2–4]. CD8+ T cells upregulate
CD103 upon combined TCR stimulation and TGF-β signaling [5–7]. Even though TGF-β production is commonly attributed to dendritic cells and T regulatory cells, differentiated CD103+ T RM are also capable of self-producing activated TGF-β1 to maintain CD103 expression on their cell surface [8]. CD103+ T RM are associated with prolonged survival in many solid tumors [4,6,9–13], including endometrial cancer (EC). Endometrial tumors are stratified into risk groups based on histology, grade, and FIGO stage, among others [14]. In addition, EC can be classified according to molecular subtype: copy number low/p53 wild-type, copy number high/p53 mutant, polymerase E mutant (POLE-mutant), and mismatch repair deficient (dMMR + MSI). POLE-mutant, dMMR, and p53-aberrant tumors are typically high-grade tumors [15]. Particularly, POLE-mutant and dMMR tumors harbor many neoantigens and are more infiltrated by immune cells, including CD103+ T RM [16–18]. CD103+ T RM, both in tumor and non-tumor-specific tissue, are marked by expression of PDCD1, ITGA6, CXCR6, and SPRY1 in lung cancer [19]. Tumor-resident CD103+ T RM expressed a unique genotype compared to non-tumor CD103+ T RM, characterized by expression of ENTPD1 (CD39) [20]. Indeed, bystander, i.e., non-tumor specific T cells, lack CD39 expression [21]. CD39, also known as ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), catalyzes the phosphohydrolysis of extracellular ATP and ADP to eventually synthesize immunosuppressive adenosine. CD39 is upregulated on activated T cells [22], regulates T cell activation and polarization, and is considered an immunosuppressive marker associated with T cell exhaustion [23,24]. CD39 has therefore been put forth as an immunoregulatory checkpoint and a new therapeutic target in cancer [25]. A further specification of T RM cells in endometrial cancer might therefore be relevant, as CD39 and CD103 co-expression identifies tumor-resident, clonally expanded, tumor- and non-tumor-specific T cells with superior cytolytic capacity [19,20]. Moreover, tumor-resident CD103+ T RM differentially express immune checkpoints such as CTLA4, TIM3, LAG3, and TIGIT, indicating T cell exhaustion due to excess antigen stimulation [9,18,19,26]. In line with this, CD103+ T RM are linked to response to immune checkpoint blockade (ICB) [27,28]. Thus, it can be hypothesized that patients with both a sufficient number of T RM cells and a specific subtype of T RM cells are likely to respond to immunotherapy/immune checkpoint blockade. However, little is known about transcriptional activity of T RM cells in situ. We studied the transcriptional profile of high-grade endometrial cancer CD39+CD103+ T RM cells in situ, after T cell activation, and after transcriptional inhibition with actinomycin D in order to elucidate core elements necessary for successful T cell reactivation. Moreover, we studied the immune profile of TIL in the context of pretreatment with actinomycin D, a platinum-like chemotherapeutic. In this study we showed that resting CD39+CD103+ T RM cells were transcriptionally active and expressed a characteristic tissue-resident transcriptional profile. Upon activation, T RM cells upregulated markers of T cell activation, cytolytic activity, and cytokine production. Secondly, we studied transcript stability and found that PMA-responsive immune genes and mitochondrial genes were particularly stable, which led us to hypothesize this differential regulation of transcript stability potentiates rapid responses upon T RM reactivation in tumors.

2. Results

2.1. CD39+CD103+ T RM and CD8+ TIL are Transcriptionally Active in Situ

We analyzed the transcriptome of CD39+CD103+ T RM and a reference population of CD8+ TIL in high-grade endometrial cancer using mRNA sequencing (summarized in Figure 1A). The reference population was randomly sorted from the CD3+CD8+ population of each of the tumor digests, but for further information, the CD39/CD103 staining of these tumors were added (Supplementary Figure S1A).

To compare transcriptional profiles in resting condition to the transcriptional profile upon activation and transcriptional inhibition, samples were either not treated (untreated) or treated with PMA/ionomycin (PMA), actinomycin D (ACT), or a combination of both. Actinomycin D is a chemotherapeutic with some similarities to platinum-based chemotherapy and is therefore also of interest in immune cells in endometrial cancer. cDNA concentrations were comparable between
CD39+CD103+ TRM and CD8+ bulk cells (Figure 1B). However, there were distinct differences between treatment conditions: the cDNA concentration increased upon activation with PMA/ionomycin and diminished upon transcriptional inhibition by actinomycin D independently of PMA treatment (TRM median 4.92 ng/µL/100 cells untreated, 0.70 ng/µL/100 cells actinomycin D, 9.44 ng/µL/100 cells PMA, and 2.48 ng/µL/100 cells combination, respectively). Principal component analysis identified actinomycin D treatment as the first component, explaining 47% of variance, and PMA/ionomycin as the second with a variance of 8% (Figure 1C). Resting, untreated, CD39+CD103+ TRM cells robustly transcribed characteristic CD8+ T cell markers such as CD3D, CD3E, CD3G, CD8A, CD8B and CD27 (Figure 1D). In addition, they expressed several checkpoints frequently found in TRM such as CTLA4, TIGIT, LAG3, HAVCR2, and PDCD1. Expression of several other T cell-related genes in resting CD39+CD103+ TRM varied: IFNG was uniformly expressed, but several TNF ligands, TNF receptors, chemokines, and chemokine receptors were expressed in some, but not all patient samples. It was noteworthy that TNF, TNFSF4, TNFSF8, and TNFSF9, all associated with T cell activation, were barely transcribed at baseline, as were most cytokine-related genes. We observed a similar expression pattern in CD8+ bulk TIL (Supplementary Figure S1D). These findings indicate that transcription in CD39+CD103+ TRM cells is ongoing during in vitro culture, and these T cells have baseline transcript expression despite their exhausted phenotype.

**Figure 1.** CD39+CD103+ TRM cells sorted from human endometrial tumors are transcriptionally active. (A) Overview of experimental set-up. CD39+CD103+ T RM cells and CD8+ TIL were sorted from human high-grade endometrial cancer digests (n = 3). Subsequently, cells remained untreated or were treated for 4.5 h with actinomycin D, or 4 h of PMA/ionomycin or pre-incubation for 30 min with actinomycin D followed by 4 h PMA/ionomycin. (B) Concentration of cDNA (ng/µL/100 cells) of CD39+CD103+ T RM cells and CD8+ TIL per treatment group. The median concentration + 95% confidence interval is depicted. (C) Principal component analysis of mRNA sequencing data of all TRM samples. The first two principal components are depicted. Individual patient samples are identified by separate colors. (D) Heatmap of a customized set of T cell markers of library size-normalized, log2-transformed counts of untreated CD39+CD103+ T RM cells from three patients. The scale applies to all similar heatmaps of CD39+CD103+ T RM cells throughout the paper.
2.2. Transcription Inhibition by Actinomycin D Reveals Distinct Differences in Transcript Stability

We studied transcript turnover and transcript stability in CD39+CD103+ TRM cells and CD8+ TIL by comparing untreated and transcriptionally halted samples treated with actinomycin D. We observed a strong decrease in the number of transcripts in both CD39+CD103+ TRM and CD8+ TIL. This was also reflected in the distribution of the volcano plots, with a distinctly larger negative fold change-tail (Figure 2A, Supplementary Figure S1B, Supplementary Table S1, and Supplementary Table S2).

**Figure 2.** Effect of actinomycin D on transcriptional activity of CD39+CD103+ TRM. (A) Volcano plot depicting differentially expressed genes (DEseq2) of CD39+CD103+ T RM cells treated with actinomycin D for 4.5 h versus untreated. Each dot represents a gene with a Benjamini–Hochberg adjusted p-value < 0.05. Differentially decreased genes are depicted as unstable, differentially increased genes as stable. (B) Gene ontology analysis of top-250 differentially stable genes performed by Panther DB. (C) Fold changes of a customized set of T cell markers upon actinomycin D treatment versus untreated CD39+CD103+ T RM and CD8+ TIL. (D) Co-functionality network of the top-250 differentially expressed genes in actinomycin D versus untreated CD39+CD103+ T RM cells with default parameters. Several Biocarta pathways with z-score >2 are annotated. (E) Median gene expression values of CD39+CD103+ T RM cells (log10 n+1), with the median value of untreated cells on the x-axis and of actinomycin D samples on the y-axis. Significant differentially expressed genes (DESeq2) are depicted for untreated (blue) and actinomycin D (orange) cells.
In actinomycin D-treated samples, 3839 genes were differentially lower expressed compared to untreated T
RM. Top differentially expressed unstable genes in actinomycin D-treated versus untreated cells included RPN2 (ribosporin II, endoplasmatic reticulum gene involved in Golgi transport), INTS6 (integrator complex subunit 6, a putative RNA helicase that interacts with RNA polymerase II), EMP3 (epithelial membrane protein 3, involved in cell proliferation and cell–cell interactions), JTB (jumping translocation breakpoint, a requirement for cytokinesis during mitosis), and UBE2A (ubiquitin conjugating enzyme E2 A, an enzyme required for post-replicative DNA damage repair). Top differentially expressed stable genes in actinomycin D-treated versus untreated samples included TRIB1 (tribbles pseudokinase 1, encoding an adapter protein involved in protein degradation) and RPS10P7 (ribosomal protein S10 pseudogene 7) (Figure 2A). In bulk CD8+ TILs, SDHB, MCAT, and CD27 were the top differentially expressed unstable genes, and IBA57 was one of the top stable genes (Supplementary Figure S1B). Notably, many unstable CD8+ TIL genes were also differentially unstable in CD39+CD103+ TRM (Supplementary Table S1 and Supplementary Table S2). To determine the molecular function of stable transcripts, we classified the top-250 differentially expressed stable genes in CD39+CD103+ TRM according to the Gene Ontology (GO) molecular function. 71% of stable genes were appointed to GO functions binding or catalytic activity (Figure 2B and Supplementary Table S3). Actinomycin D is a chemotherapeutic that inhibits transcription, but it is sometimes also used as a read-out for platinum-based chemotherapy. We therefore further elaborated on the effect of actinomycin D on cytotoxic T cell characteristics and hallmark functions by comparing fold-changes of key immune-related genes. Expression of several TNF ligands and receptors (TNFSF4, TNFSF14, TNFRSF1A, TNFRSF4, TNFRSF12A, and TNFRSF13C) showed a negative fold change upon actinomycin D treatment, as did cytokine genes CCL3, CXCL2, CXCL8, and CXCR6 and interleukin (receptor) genes IL16, IL24, IL15RA, and IL27R (Figure 2C). By contrast, TNFSF9, TNFRSF10A, IL10, IL13, IL21, and IL22 were relatively stable under actinomycin D. To study the pathway involvement of stable genes in CD39+CD103+ TRM, we generated a co-functionality network with an integrative tool that predicts gene functions based on a guilt-by-association (GBA) strategy utilizing >106,000 expression profiles [29]. The top-250 stable genes (maximum number for this analysis) were analyzed with default parameters for Biocarta pathways (Figure 2D). We observed two large sub-networks: genes in sub-network 1 were associated with or assigned to take part in the cell cycle, whereas sub-network 2 contained immunity-related genes. Two smaller sub-networks were associated with complement and Wnt/VEGF/mTOR signaling (Figure 2D). Interestingly, among the top pathways in the immune cluster were not only the T cell receptor pathway and cytotoxic T cell/cytotoxicity pathway, but also the B lymphocyte and NK-T pathways. We have previously hypothesized that CD103+ TIL affect B cell migration via CXCL13 production, which may in part explain the association with B cell-related genes/pathways [18].

Although most transcripts decreased after actinomycin D treatment, we also noticed a steady or even increased number of transcripts for some genes. Thus, we compared median counts of untreated samples and actinomycin-treated samples (Figure 2E). Many of the significantly enriched transcripts were mitochondrial genes, such as MT-ND4, MT-CYB, MT-COX1, MT-COX2, and MT-ATP6. Median expression of EIF1 and EIF4, both associated with translation initiation, also increased upon actinomycin treatment. Several genes were not expressed in untreated samples but were found in actinomycin D-treated cells, suggesting de novo synthesis due to transcriptional arrest. These genes included USP36 (deubiquitinase), MYO6 (actin-based motor molecules), ZNF528 (DNA-binding transcription activity), AP000648.4 and EMC9 (ER membrane protein). Taken together, we found increased transcript stability in cell cycle and immunity-related genes, in particular in several T
RM-associated genes and mitochondrial genes.
2.3. Stimulation with PMA/Ionomycin Induces an Activation-Responsive Genotype in Tumor-Infiltrating Lymphocytes

To elucidate biological and transcriptional processes in human tumor-associated TRM cells upon re-activation, we analyzed CD39+CD103+ TRM cells and heterogeneous CD8+ TIL treated with PMA/ionomycin. Activated CD39+CD103+ TRM differentially expressed 589 genes (Supplementary Table S4). TWNK (twinkle mtDNA helicase, involved in mitochondrial DNA replication and energy formation), PLEK (pleckstrin, induces reorganization of the cytoskeleton, involved in lymphocyte spreading and immune synapse formation), IL21 (interleukin 21) and FOS (FOS proto-oncogene) were top hits in this analysis (Figure 3A).

Figure 3. CD39+CD103+ TRM cells differentially upregulate genes associated with immunity, cell cycle, and the tumor microenvironment. (A) Volcano plot depicting differentially expressed genes (DEseq2) of CD39+CD103+ TRM cells treated with PMA/ionomycin for four hours versus untreated cells. Each dot represents a gene with a Benjamini–Hochberg adjusted p-value < 0.05. (B) Venn diagram showing overlap of differentially expressed genes of PMA/ionomycin-treated CD39+CD103+ TRM cells and significantly stable genes after actinomycin D treatment. (C) Co-functionality network of the top-250 differentially expressed genes in PMA/ionomycin-treated cells versus untreated CD39+CD103+ TRM cells with default parameters. Several Biocarta pathways with z-score > 2 are annotated.

TWNK, PLEK, IL21, and several FOS gene family members (FOSL, FOSB) were also differentially expressed in CD8+ TIL (Supplementary Figure S1C and Supplementary Table S5), but FOS was not. FOS is thought to play an important role in signal transduction, cell proliferation, and differentiation via SMAD3/SMAD4/JUN/FOS complex upon TGF-β stimulation. Indeed, it is very likely that CD103+, but not CD8+ bulk TIL were exposed to TGF-β in vivo, as we and others have previously shown that CD103 expression is TGF-β dependent [5,6]. Other differentially expressed genes in activated TRM...
were relatively stable upon actinomycin treatment were particularly responsive to PMA.

A third smaller, but distinctly separate, network of IL13+ (GM-CSF) exhibited a somewhat intermediate profile, as combination of actinomycin (Figure 3B and Supplementary Figure S1E).

The overlap in sub-network formation between actinomycin-stable genes and PMA-upregulated populations, indicating the di

IL13 pattern in qPCR was very similar compared to mRNA expression. The qPCR for validated these findings by comparing log2-normalized expression between di

Figure S1D, Supplementary Table S4, and Supplementary Table S5). Interestingly, several genes that were relatively stable upon actinomycin treatment were particularly responsive to PMA/ionomycin (Figure 3B and Supplementary Figure S1E).

To validate our findings on the protein level, we first studied production of CD8+ TIL expressed some IFNG in resting condition, but minimal to no TNF, IL2, IL10, and IL13. CD39+CD103+ TRM cells expressed low levels of CSF2 (GM-CSF) in resting conditions, whereas CD8+ bulk cells did not (Figure 4A). Upon activation, both CD39+CD103+ TRM and CD8+ TIL expressed IFNG, TNF, IL2, IL10, IL13, IL21, and CSF2 mRNA (Figure 4A). The pattern in qPCR was very similar compared to mRNA expression. The qPCR for IL13 was positive in water controls, therefore we have not included these and rendered them not determined. The normalized counts and Ct-values of GAPDH remained stable in different treatment settings in both populations, indicating the differences observed in cytokine genes are indeed a gene-specific effect of the PMA/ionomycin and actinomycin D treatments.

We observed a different response to actinomycin D in samples that were treated with both PMA and actinomycin. Despite pre-incubation with actinomycin, transcription of IFNG, TNF, and IL2 was barely affected, whereas transcription of IL10 and IL13 strongly decreased. IL21 and CSF2 (GM-CSF) exhibited a somewhat intermediate profile, as combination of actinomycin + PMA lowered transcription, but did not halt it completely (Figure 4A,B).

To validate our findings on the protein level, we first studied production of CD8+-associated cytokines IFN-γ, TNF-α, and IL-2 in endometrial cancer cytotoxic TIL. Endometrial cancer digestes were incubated with a protein transport inhibitor containing Brefeldin A with or without PMA/ionomycin.

t-Stochastic neighbor embedding (tSNE) of pooled data from three patient digestes showed subsets of PMA-activated CD8+ TIL produced IFN-γ, TNF-α, and/or IL-2 (Figure 5A), whereas untreated cells did not (Figure 5A).
Supplementary Figure S2A,B). Pretreatment with actinomycin D followed by PMA resulted in a median 3.7% production of GM-CSF (Figure 5D). However, within unstimulated cells, only 2.75% produced GM-CSF, 1.475% of cells with an extensive cytokine repertoire that includes production of IL-21 and GM-CSF. but not all, cytokines (Figure 4A,B and Figure 5F). Taken together, cytotoxic TIL are polyfunctional T cells with an extensive cytokine repertoire that includes production of IL-21 and GM-CSF.

Of PMA-treated TIL, 31.8% (median of 6 samples) produced IFN-γ, TNF-α, IL-2, or a combination of these (Figure 5B,C), whereas only 3.8% of untreated cells produced any cytokine. In fact, 21.8% of activated cytokine-producing TIL were polyfunctional and expressed two or three of the studied cytokines (Figure 5C). Our sequencing and qPCR data indicated that T<sub>RM</sub> and CD8<sup>+</sup> TIL might have a more extensive cytokine repertoire that also includes IL-10, IL-13, IL-21, and GM-CSF. To validate this, we performed a flow cytometry experiment of PMA/ionomycin. t-Stochastic neighbor embedding (tSNE) of pooled data from three patient digests indicating the differences observed in cytokine genes are indeed a gene-specific effect of the PMA/ionomycin. t-Stochastic neighbor embedding (tSNE) of pooled data from three patient digests. PMA/ionomycin. t-Stochastic neighbor embedding (tSNE) of pooled data from three patient digests.
2.5. T<sub>RM</sub>-Genes and PMA-Responsive Genes are Associated with Response to Immune Checkpoint Blockade in Publically Available Sequencing Data

Finally, we determined whether the T<sub>RM</sub> and PMA-induced gene signature were associated with response to immune checkpoint inhibition. Therefore, we turned to publicly available sequencing data of melanoma samples that were taken prior to and upon treatment with immune checkpoint inhibitor nivolumab [30]. Our hypothesis was that PMA-responsive genes would be particularly seen in nivolumab-treated, i.e., reactivated, samples. Riaz et al. provided a list of differentially expressed genes of responders (complete response or partial response) versus non-responders upon treatment. Interestingly, several of our T<sub>RM</sub>-signature, stable, or PMA-responsive genes were indeed reported differentially expressed in responders during treatment, including CD8, CD27, PDCD1, CTLA4, LAG3, IFNG, PLEX, TNFRSF9, TNFRSF10A, CCL3, and CCL4 (Riaz et al., Supplementary Figure S3A–C) [30]. We also assessed expression of activation-responsive immune genes TNF, IL21, IL10, IL13, and CFS2 in the ICB melanoma dataset, and found that IFNG, TNF, and interleukins IL21 and

---

**Figure 5.** Activated CD8+ T cells are polyfunctional T cells that are responsive to (re)activation. (A) t-stochastic neighbor embedding plots of flow cytometry data of three endometrial tumor digests stained for CD3, CD8, IFN-γ, TNF-α, IL-2, and Zombie Aqua (live/dead stain). (B) Exemplary flow cytometry image of CD8+ T cells stained for CD3, CD8, IFN-γ, TNF-α, and IL-2. (C) Endometrial digests stained as described in (B) (n = 6). Percentages of untreated cells (blue) or cells activated by 4-h incubation with PMA/ionomycin (red) that produce no, one, two, or three of the depicted cytokines. Bars depict the median. (D) Endometrial cancer digests (n = 7) stained for CD3, CD8, IFN-γ, TNF-α, IL-2, and Zombie Aqua; 4 of these digests were additionally stained for IL-13 and IL-21, and 3 digests for IL-10 and GM-CSF. Percentages of untreated CD8+ TIL and CD8+ TIL activated by 4-h incubation with PMA/ionomycin positive for either of the depicted cytokines. Bars depict the median. (E) Exemplary flow cytometry images of CD8+ TIL stimulated for 4 h with PMA/ionomycin as depicted in D. (F) Heatmap of a customized set of T cell markers of library size-normalized, log2-transformed counts of PMA/ionomycin- and PMA/ionomycin + actinomycin D-treated CD39+CD103+ T<sub>RM</sub> cells.
IL10 seemed to increase upon treatment in responders (Supplementary Figure S3C), even though they were not differentially expressed. However, IL21R was differentially expressed (DE) upon treatment irrespective of response, as were several IL2 receptor genes. Taken together, a number of genes associated with TRM and PMA signatures were differentially expressed upon treatment with nivolumab in melanoma patients.

3. Discussion

We have analyzed baseline transcription and transcriptional stability in CD39+CD103+ TRM in high-grade endometrial cancer and assessed transcriptional and translational responses upon T cell activation. In this study, we showed that resting CD39+CD103+ TRM cells were transcriptionally active and expressed a characteristic tissue-resident transcriptional profile comparable to TRM in other tumor types [31]. We observed expression of ITGAE, ENTPD1, IFNG, TNFRSF9 (CD137), TNFSF10, EGR2, chemokines CCL3, CCL4, and CCL5, and chemokine receptors CXCR3, CXCR4 and CXCR6. This is in line with the expression profile of CD103+ tumor-resident T cells in lung cancer, breast cancer, and ovarian cancer [9,18,19,26,32]. CD39+CD103+ TRM cells are associated with an improved prognosis in many solid tumors [33] and CD103+ TRM have been linked to response to immune checkpoint blockade [28,34]. This is further strengthened by the finding that the loss of E-cadherin, the receptor for the CD103/β7 integrin, inhibits responses to immune checkpoint blockade in melanoma [35]. In spite of the prognostic effect of CD103+(CD39+)+ TRM, their phenotype is often considered exhausted and functionally impaired across tumor types [9,19,26,36]. TRM in our study indeed expressed several immune checkpoints including HAVCR2, LAG3, CTLA4, and PDCD1. Despite expression of these inhibitory receptors, CD39+CD103+ TRM cells in this study upregulated markers of T cell activation, cytolytic activity, and cytokine production upon activation with PMA/β2m/lysin. In line with this, Abd Hamid et al. showed that activated TRM cells express superior effector and resident memory profiles and have higher metabolic activity and mitochondrial capacity compared to non-activated controls [8]. Moreover, activated T cells in our study retained the functional capacity to produce cytokines TNF-α, IFN-γ, and IL-2. T cells that produce all three of these cytokines (triple-producers) are associated with superior activity upon rechallenge in viral infections, suggesting this may also hold true in tumor immunity. A subset of triple-producers also produced IL-21 and GM-CSF ex vivo, but not IL-13 or IL-10, even though we also observed mRNA expression of IL10 and IL13 in activated TRM. We do not fully comprehend why IL21 and CSF2 were translated, whereas IL10 and IL13 were not. We speculate that this could depend on environmental cues within the tumor, and therefore perhaps does not occur in vitro. Production of IL-21 by cytotoxic T cells is not extensively described, but IL21 mRNA was found in PD1-high CD8+ T cells in a CAR-T solid tumor mouse model [37]. IL-21 promotes effector functions in naïve CD8+ T cells [38] and is important in CD8+ T cell survival, function, and memory formation [39]. Indeed, CD8+ T cells incubated with IL-21 showed enhanced tumor regression in an adoptive cell transfer mouse study [40]. Moreover, IL-21 stimulates B cell differentiation, memory B cell and plasma cell formation. We hypothesize that this may be an important mode of action for TRM-produced IL-21, as we have previously shown that CD103+ TRM produce CXCL13 and associate with B cells and tertiary lymphoid structures in gynecological malignancies [18]. In line with this, Xiao et al. showed that IL-21 produced by CD8+ T cells promoted IgG production by matched B cells in vitro [41]. CD39+CD103+ TRM also differentially expressed CSF2 and activated CD8+ TIL produced GM-CSF ex vivo. GM-CSF, a potent immunostimulatory cytokine, is frequently used as an adjuvant in cancer vaccination trials and is linked to increased T cell recruitment to the tumor microenvironment [42].

We observed expression of SPRY1, SPRY2, NR4A2, and NR4A3 in TRM cells, and expression of these genes increased after T cell activation with PMA. Similarly, expression of SPRY1 and NR4A3 has been observed in CD103+ TRM in lung cancer [19]. NR4A transcription factors and SPRY are initiated by NFAT (nuclear factor of activated T cells), and NFAT plays an important role in upregulation of CD103 on CD8+ T cells. NR4A knockdown in CD8+ CAR-T cells in a solid tumor mouse model
increased CD8+ T cell effector functions and induced tumor regression [43]. Lack of Sprouty 1 and 2 enhances survival of effector CD8+ T cells [44], and mice with a T cell-selective deletion of Spry1 show enhanced responses to a tumor vaccine [45]. Reactivation of T cells as mimicked by PMA activation thus seems to initiate negative feedback mechanisms in T cells, suggesting that (re)activated T cells are functionally halted by endogenous negative feedback loops. In conclusion, CD39+CD103+ T_{RM} cells and CD8+ TIL in endometrial cancer are responsive to reactivation and produce both classical and non-classical cytokines that can influence both T cell and B cell function. Moreover, targeting activation-induced negative feedback mechanisms that halt T_{RM} activation, such as NR4A, could perhaps ameliorate responses to immune checkpoint blockade.

We have analyzed transcript stability in CD103+CD39+ T_{RM} by comparing untreated cells to cells treated with actinomycin D for 30 min followed by four hours of medium incubation prior to sequencing. Transcript stability prolongs the opportunity for translation, thereby increasing the bioavailability of the encoded protein. It is relevant to stabilize expression of (synthetic) mRNA in vitro and in vivo, as exploiting the unique properties of mRNA for therapeutic purposes gains more attention [46–50]. Von Niessen et al. have described how 3′ untranslated regions (UTRs) can augment the translation of synthetic mRNA in the context of vaccine antigens to elicit a T cell immune response [46]. As there are multiple genes whose 3′ UTR regulate mRNA stability, this could be a potential strategy to control therapeutic gene expression in viral vectors or vaccines. Mitochondrial transcripts do not possess a 3′ UTR, yet mitochondrial genes were among the most stable transcripts in our data. The stability of mitochondrial genes has not been elucidated fully but could perhaps be used in a similar manner as 3′ UTRs to stabilize desired mRNA.

We observed increased expression of several genes in actinomycin D-treated cells compared to controls, which could be the novo transcription via actinomycin D-insensitive routes. This included USP36, ZNF528, MYO6, and EMC9. One could hypothesize that the transcriptional halt provided by actinomycin does not affect all genes evenly, thereby allowing some genes to be less inhibited. It has been suggested that actinomycin D has preferential binding in CGG-triplet repeat sequences [51]. It could also be that these transcripts were not de novo described, but transcripts were relatively more abundant due to the decrease in the total number of transcripts after actinomycin D treatment and, therefore, they were found in this group. However, we have used a high concentration of actinomycin D that should be sufficient to inhibit all three eukaryotic polymerases [52], and a commonly used pre-incubation time [53]. Indeed, we observed almost complete inhibition of RNA synthesis in the actinomycin D monotherapy group, indicating effective inhibition of mRNA transcription.

Interestingly, several actinomycin-stable immune-related genes were particularly responsive to PMA activation. We hypothesized that the stability of these genes reflects a prolonged but dormant immune response, rendering these T_{RM} cells primed to rapidly respond once fully activated. Actinomycin D is a chemotherapeutic that is commonly used in several tumor types, particularly in sarcomas. In addition, it is sometimes used in vitro studies to mimic the effect of platinum-based chemotherapy [54]. Platinum-based compounds act by binding to DNA and inhibiting its replication by forming cross-links in the DNA that block transcription, eventually resulting in cell death of dividing cells [55]. Actinomycin D inhibits RNA polymerase function by binding DNA at the transcription initiation complex, thereby preventing elongation of the RNA. Thus, effects of platinum-based compounds and actinomycin D on transcription in particular are presumed to be similar. This provides us with an opportunity to estimate TIL activation in the context of a read-out for adjuvant chemotherapy in patients with high-risk endometrial cancer. Remarkably, IFNG, TNF, and IL2 were still increased (IFNG) or even appeared to be de novo transcribed (TNF and IL2) despite the inhibitory effect of actinomycin D on transcription compared to untreated samples. The hallmark cytokine profile of cytotoxic CD39+ T_{RM} cells does not seem to be affected by actinomycin D, suggesting that T_{RM} cells in vivo may preserve cytokine-producing capacities during chemotherapy. Some studies suggest platinum-based chemotherapy not only induces apoptosis via DNA damage but may also have immunogenic effects [56]. In addition, our group has recently studied the immune composition prior
and after neoadjuvant platinum-based chemotherapy and found that the number of tumor-infiltrating lymphocytes in ovarian cancer was not affected by chemotherapy, although MHC-I expression was lower [57]. This is in line with findings by others who found CD8+ TIL infiltration to remain stable or even increase after neoadjuvant platinum-based chemotherapy in ovarian cancer [58–61], implying that platinum-based chemotherapy may augment a pre-existing immune response. As endometrial cancer, particularly MSI and POLE-mutant, is generally more immunogenic than ovarian cancer, this holds promise for patients with (advanced) endometrial cancer. In our study characteristic markers of T_{RM} cells in EC were responsive to PMA activation and were relatively unaffected by chemotherapy simulation, implying that a combination strategy of chemotherapy followed by immunotherapy may be an interesting option for further studies.

We have found that many of the transcriptional processes upon activation were not specific to CD39+CD103+ T_{RM} but seemed somewhat inherent to CD8+ TIL as a whole population. Upon examination of the data, we did observe large similarities in the response pattern between T_{RM} and CD8+ TIL. We have specifically made use of a non-otherwise specified CD8+ TIL population, as we were interested to study whether observed effects were also visible in a general population as you find it in a tumor. In line with previous experiments, the fraction of CD39+CD103+ TIL varied per patient, and therefore provided a representative image of the well-known variation in immune infiltrate in human tumors. As mentioned previously, high-grade endometrial cancer is a heterogeneous group of tumors. In this study, we performed sequencing analyses on two high-grade dMMR/MSI endometrioid tumors and one high-grade p53-mutant pMMR serous tumor. We did not observe general differences in transcription, and both PMA and actinomycin D responses were consistent between dMMR/MSI and MSS cases of high-grade EC, although we stress the small size of our group. This suggests that our findings are of interest to all high-grade EC.

Taken together, our findings showed that CD39+CD103+ T_{RM} cells in high-grade endometrial cancer are polyfunctional T cells with a reactivation-responsive repertoire, despite their exhausted phenotype, and these T_{RM} express a variety of immune checkpoints. Secondly, CD39+CD103+ T_{RM} showed increased transcript stability of PMA-responsive and mitochondrial genes, which may potentiate rapid responses upon T_{RM} cell reactivation in tumors. Thirdly, T_{RM} cells seem to incorporate activation-induced negative feedback mechanisms that halt T_{RM} activation, and targeting these may be of interest in optimizing response to immune checkpoint blockade.

4. Materials and Methods

4.1. Tumor Material Preparation

Endometrial cancer digests were obtained from surgical waste material collected in the University Medical Center Groningen, The Netherlands. Patients had given consent to use surgical waste material for research purposes. Samples were processed anonymously and assigned a coding number prior to storage. According to Dutch law no approval from our institutional review board was needed. Of the material used for sequencing, two tumors were high-grade endometrioid adenocarcinomas with MMR deficiency (FIGO IA, loss of PMS2, and FIGO IB, loss of MSH2 and MSH6, respectively) and the third tumor was of high-grade serous p53-mutant adenocarcinoma histology with proficient mismatch repair proteins, FIGO IIIC2. Tumors were cut into approximately 1cm³, enzymatically digested in RPMI medium (Gibco, Paisley, UK) with 1 mg/µL collagenase type IV (Gibco Life Technologies, Grand Island, NY, USA) and 12.6 µg/mL recombinant human DNase (Pulmozyme, Roche, Woerden, the Netherlands) for 30 min at 37 °C or overnight at room temperature. Digests were filtered using 70 µm cell strainers (Falcon) and enriched for peripheral blood mononuclear cells (PBMCs) using Ficoll-Paque PLUS (GE Healthcare Life Sciences, Marlborough, MA, USA). Cells were cryopreserved in fetal calf serum (FCS) with 10% dimethylsulfoxide and stored in liquid nitrogen until further use.
4.2. Isolation of PBMCs from Healthy Volunteers

Human PBMCs were isolated via Ficoll-Paque density gradient centrifugation (Ficoll-Paque PLUS, GE Healthcare Life Sciences, Marlborough, MA, USA) from buffy coats of healthy volunteers. Buffy coats were purchased from Sanquin and all donors gave informed consent (Sanquin Blood Supply, Groningen, the Netherlands). Isolated PBMCs were cryopreserved in FCS with 10% dimethylsulfoxide until use.

4.3. CD39+CD103+CD8+ and CD8+ T Cell Sorting

Endometrial cancer tumor digests from three endometrial cancer patients were thawed in RPMI + 10% fetal calf serum. Each digest was split four ways; one part remained untreated, one part was incubated with phorbol myristate acetate (PMA)/ionomycin (1x Cell Stimulation Cocktail, consist of 81 nM PMA and 1.34 µM Ionomycin, eBioscience, 00-4970-93, Waltham, MA, USA) for four hours, one part was treated with actinomycin D for 4.5 h (5 µg/mL, A1410-2mg, Sigma-Aldrich), and one part was pre-treated with 30 min of actinomycin D followed by four hours of PMA/ionomycin. All conditions were incubated at 37 °C. Next, samples were washed with PBS 2% FCS and stained with CD103-FITC, CD39-APC, CD3-PE, and CD8a-BV421 for 30 min at 4 °C (Supplementary Table S6). Cells were washed and filtered using a 35 µm strainer (Falcon). Propidium iodide (1 µg/mL) was used to exclude dead cells. Per treatment condition, 100 live CD3+CD8+ or 100 live CD3+CD8+CD39+CD103+ cells were sorted from all digests. Cells were sorted on a Beckman Coulter MoFlo Astrios sorter.

4.4. mRNA Sequencing CD39+CD103+CD8+ and CD8+ Tumor-Infiltrating Lymphocytes

Samples were sorted in 2 µL lysis buffer (0.2% Triton X-100 (Sigma-Aldrich) and 2U RNase inhibitor (Takara)) with 1 µL 10 µM oligo-dT primer and 1 µL 10 mM dNTP mix (Thermo Scientific). After sorting, the plate was spun down and incubated at 72 °C for 3 min. We used a modified SMARTseq2 protocol using custom-made primers (Supplementary Table S7), as described previously [18]. In brief, SmartScribe reverse transcriptase (Westburg-Clontech) and a template switching oligo (BC-TSO) were used to generate cDNA. Next, a PCR preamplification step was done with KAPA HiFi HotStart Ready Mix (Roche Diagnostics) and a custom-made PCR primer. The cDNA samples were purified using Ampure XP beads (Beckman Coulter) in a ratio of 0.6:1 (Ampure beads: cDNA). Samples were analyzed on a 2100 Bioanalyzer using a PerkinElmer LabChip GX high-sensitivity DNA chip (Agilent) and on a Qubit™ 4 Fluorometer (ThermoFisher Scientific) according to the manufacturers’ instructions. 500 pg of each sample were tagmented and N7xx and S5xx index adapters were used for barcoding according to the Illumina Nextera XT DNA sample preparation kit (Illumina). Thereafter, samples were purified with Ampure XP beads (ratio 0.6 Ampure: 1 cDNA) and analyzed on a 2100 Bioanalyzer. Samples were equimolar pooled (4 nM) and samples were sequenced on an Illumina Nextseq500 2500 using 75 bp single-end reads. The obtained mRNA sequencing data was demultiplexed into individual FASTQ files followed by alignment to the human reference genome hg38 using STAR (version 2.5.2).

4.5. qPCR of mRNA Sequencing Samples and Peripheral Blood CD8+ T Cells

Primers for GAPDH, IL-21, IL-13, IL-10, GMSC-F, TNFα, IFNγ, and IL-2 were ordered from Invitrogen Europrim (Supplementary Table S8). We performed qPCR in 384 well plates on a Bio-rad CFX384 Real-Time System. For each qPCR, a 0.5 µL cDNA sample (the same purified cDNA used for tagmentation) was used. Each reaction consisted of a final concentration of 1x PCR buffer without Magnesium (Invitrogen), 2.5 mM MgCl2 (Invitrogen), 0.2 mM dNTP mix (Invitrogen), 0.5 U Taq DNA polymerase (Invitrogen), 0.1 µM of each primer, 1x Evagreen dye (Biotium), and 0.5 µL cDNA.
4.6. Flow Cytometry

Endometrial cancer digests (n = 12) or frozen peripheral blood mononuclear cells were thawed, washed, and centrifuged. Pellets were resuspended in RPMI with 10% FCS. Half of each sample was incubated with PMA/ionomycin (eBioscience 1× Cell Stimulation Cocktail) for 4 h at room temperature, and all samples were incubated with a protein transport inhibitor to enable intracellular cytokine staining (1:1000, BD GolgiPlugs™ Protein Transport Inhibitor, Thermo Fisher Scientific, BD555029, Waltham, MA, USA). Cells were stained with Zombie Aqua (Zombie Aqua™ Fixable Viability Kit, #423101, BioLegend) for 15 min, fixed, and permeabilized according to the manufacturer’s protocol (FIX & PERM™ Cell Permeabilization Kit, #GAS003, ThermoFisher Scientific), followed by incubation with antibodies for CD3, CD8α, TNF-α, IFN-γ, IL-2 with either IL-21 and IL-13 or IL-10, and GM-CSF (Supplementary Table S6). Samples were incubated at room temperature for 15 min, washed and suspended in PBS + 2% FCS. Samples were analyzed on FacsVerse (BD Biosciences) and results were analyzed with Cytobank premium software (cytobank.org).

4.7. Publically Available Sequencing Data

Fragments per kilobase million (FPKM) values and clinical data of melanoma samples prior and during Nivolumab treatment, as previously published by Riaz et al., were downloaded from the Gene Expression Omnibus (GEO) access number GSE91061 [30].

4.8. Statistics

Data were analyzed in R (R software, version 3.6.1) and GraphPad Prism (GraphPad Software Inc.). Differential expression was determined with DESeq2 package (1.26.0) in R, with a Benjamini–Hochberg correction. Heatmaps were visualized with the heatmap2 package (1.0.12) in R. Guilt-by-association analysis was performed in Genet-ICA Network (manuscript in preparation) with default parameters and Biocarta pathways (accessible via http://www.genetica-network.com) [29]. Pathways with a z-score of >2 were considered relevant. Heatmaps of melanoma data were made with ComplexHeatmap package (2.2.0) and boxplots were made with ggplot2 package (3.3.0) in R. Throughout the work, significance was determined as (adjusted) p-value < 0.05.

Supplementary Materials: Supplementary materials can be found at http://www.mdpi.com/1422-0067/21/11/3770/s1.

Author Contributions: Conceptualization, H.W.N. and M.d.B.; methodology, M.d.B., D.C.J.S., and R.S.N.F.; validation, H.H.W., N.v.R., and A.P.; formal analysis, H.H.W. and M.d.B.; investigation, H.H.W., N.v.R., and A.P.; resources, A.P., D.C.J.S., N.v.R., and H.H.W.; data curation, M.d.B. and D.C.J.S.; writing—original draft preparation, H.H.W.; writing—review and editing, N.v.R., M.d.B., H.W.N., and D.C.J.S.; visualization, H.H.W. and M.d.B.; supervision, H.W.N. and M.d.B.; project administration, M.d.B.; funding acquisition, M.d.B. and R.S.N.F. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Dutch Cancer Society/Alpe d’Huzes grants UMCG 2014–6719 (to M. de Bruyn), and RUG 2013-5960 (to R.S.N. Fehrmann). The Netherlands Organization for Scientific Research (NWO-VENI grant) 916-16025 (to R.S.N. Fehrmann).

Acknowledgments: The authors would like to thank Arjan Kol, Geert Mesander, Johan Teunis, and Karina Hoekstra-Wakker for their technical assistance.

Conflicts of Interest: H.W. Nijman reports receiving commercial research funding from Aduro Biotech Europe, BionTech, and DCPrime, has ownership interest in ViciniVax, and is a consultant/advisory board member for ViciniVax. M. de Bruyn reports receiving commercial research funding from Aduro Biotech Europe and DCPrime. All other authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Abbreviations

ACT  Actinomycin D
CD   Cluster of Differentiation
EC   Endometrial cancer
FCS  Fetal calf serum
FIGO International Federation of Gynecology and Obstetrics
GM-CSF Granulocyte Macrophage – Colony Stimulating Factor
ICB  Immune checkpoint blockade
IL   Interleukin
MMR Mismatch repair
- dMMR Mismatch repair deficient
- pMMR Mismatch repair proficient
MSI  Microsatellite instability
MSS  Microsatellite stability
ND   Not determined
PBMC Peripheral blood mononuclear cells
PD   Progressive disease
PRCR Partial response/complete response
PMA Phorbol myristate acetate
POLE Polymerase epsilon
SD   Stable disease
TIL  Tumor-infiltrating lymphocytes
TRM Tissue-resident memory cell
tSNE t-Stochastic neighbor embedding
UNK Unknown
UTR Untranslated region

References

1. Barnes, T.A.; Amir, E. HYPE or HOPE: The prognostic value of infiltrating immune cells in cancer. Br. J. Cancer 2017. [CrossRef]
2. Franciszkiewicz, K.; Le Floc’h, A.; Boutet, M.; Vergnon, I.; Schmitt, A.; Mami-Chouaib, F. CD103 or LFA-1 engagement at the immune synapse between cytotoxic T cells and tumor cells promotes maturation and regulates T-cell effector functions. Cancer Res. 2013, 73, 617–628. [CrossRef]
3. Le Floc’h, A.; Jalil, A.; Franciszkiewicz, K.; Validire, P.; Vergnon, I.; Mami-Chouaib, F. Minimal engagement of CD103 on cytotoxic T lymphocytes with an E-cadherin-Fc molecule triggers lytic granule polarization via a phospholipase Cγ-dependent pathway. Cancer Res. 2011, 71, 328–338. [CrossRef]
4. Komdeur, F.L.; Prins, T.M.; van de Wall, S.; Plat, A.; Wisman, G.B.A.; Hollema, H.; Daemen, T.; Church, D.N.; de Bruyn, M.; Nijman, H.W. CD103+ tumor-infiltrating lymphocytes are tumor-reactive intraepithelial CD8+ T cells associated with prognostic benefit and therapy response in cervical cancer. Oncoimmunology 2017. [CrossRef]
5. Mokrani, M.; Klibi, J.; Bluteau, D.; Bismuth, G.; Mami-Chouaib, F. Smad and NFAT Pathways Cooperate To Induce CD103 Expression in Human CD8 T Lymphocytes. J. Immunol. 2014, 192, 2471–2479. [CrossRef]
6. Komdeur, F.L.; Wouters, M.C.A.; Workel, H.H.; Tijans, A.M.; Terwindt, A.L.J.; Brunekreeft, K.L.; Plat, A.; Klip, H.G.; Eggink, E.A.; Leffers, N.; et al. CD103+ intraepithelial T cells in high-grade serous ovarian cancer are phenotypically diverse TCRαβ+ CD8αβ+ T cells that can be targeted for cancer immunotherapy. Oncotarget 2016. [CrossRef]
7. Franciszkiewicz, K.; Le Floc’h, A.; Jalil, A.; Vigant, F.; Robert, T.; Vergnon, I.; Mackiewicz, A.; Benihoud, K.; Validire, P.; Chouaib, S.; et al. Intratumoral induction of CD103 triggers tumor-specific CTL function and CCR5-dependent T-cell retention. Cancer Res. 2009, 69, 6249–6255. [CrossRef]
8. Abd Hamid, M.; Colin-York, H.; Khalid-Alham, N.; Browne, M.; Cerundolo, L.; Chen, J.L.; Yao, X.; Rosendo-Machado, S.; Waugh, C.; Maldonado-Perez, D.; et al. Self-Maintaining CD103+ Cancer-Specific T Cells Are Highly Energetic with Rapid Cytotoxic and Effector Responses. *Cancer Immunol. Res.* 2020. [CrossRef]

9. Ganesan, A.-P.; Clarke, J.; Wood, O.; Garrido-Martin, E.M.; Chee, S.J.; Mellows, T.; Samaniego-Castruita, D.; Singh, D.; Seumois, G.; Alzetani, A.; et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. *Nat. Immunol.* 2017, 18, 940–950. [CrossRef]

10. Wang, B.; Wu, S.; Zeng, H.; Liu, Z.; Dong, W.; He, W.; Chen, X.; Dong, X.; Zheng, L.; Lin, T.; et al. CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder. *J. Urol.* 2015, 194, 556–562. [CrossRef]

11. Djenidi, F.; Adam, J.; Goubar, A.; Durgeau, A.; Meurice, G.; de Montpreville, V.; Validire, P.; Besse, B.; Mami-Chouaib, F. CD8+CD103+ Tumor-Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients. *J. Immunol.* 2015, 194, 3475–3486. [CrossRef] [PubMed]

12. Webb, J.R.; Milne, K.; Watson, P.; DeLeeuw, R.J.; Nelson, B.H. Tumor-infiltrating lymphocytes expressing the tissue resident memory marker cd103 are associated with increased survival in high-grade serous ovarian cancer. *Clin. Cancer Res.* 2014, 20, 434–444. [CrossRef] [PubMed]

13. Workel, H.H.; Komdeur, F.L.; Wouters, M.C.A.; Plat, A.; Klip, H.G.; Eggink, F.A.; Wisman, G.B.A.; Arts, H.J.G.; Oonk, M.H.M.; Mourits, M.J.E.; et al. CD103 defines intraepithelial CD8+ PD1+ tumour-infiltrating lymphocytes of prognostic significance in endometrial adenocarcinoma. *Eur. J. Cancer* 2016, 60, 1–11. [CrossRef] [PubMed]

14. Soslow, R.A.; Tornos, C.; Park, K.J.; Malpica, A.; Matias-Guiu, X.; Oliva, E.; Parkash, V.; Carlson, J.; Glenn McCluggage, W.; Blake Gilks, C. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. *Int. J. Gynecol. Pathol.* 2019. [CrossRef]

15. McAlpine, J.; Leon-Castillo, A.; Bosse, T. The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. *J. Pathol.* 2018. [CrossRef]

16. Eggink, F.A.; Van Gool, I.C.; Leary, A.; Pollock, P.M.; Crosbie, E.J.; Milesklin, L.; Jordanova, E.S.; Adam, J.; Freeman-Mills, L.; Church, D.N.; et al. Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition. *Oncimmunology* 2016, 6, e1264565. [CrossRef]

17. Ramchander, N.C.; Ryan, N.A.J.; Walker, T.D.J.; Harries, L.; Bolton, J.; Bosse, T.; Evans, D.G.; Crosbie, E.J. Distinct Immunological Landscapes Characterize Inherited and Sporadic Mismatch Repair Deficient Endometrial Cancer. *Front. Immunol.* 2020. [CrossRef]

18. Workel, H.H.; Lubbers, J.M.; Arnold, R.; Prins, T.M.; van der Vlies, P.; de Lange, K.; Bosse, T.; van Gool, I.C.; Eggink, F.A.; Wouters, M.C.A.; et al. A Transcriptionally Distinct CXCL13+CD103+CD8+ T-Cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer. *Cancer Immunol. Res.* 2019. [CrossRef] [PubMed]

19. Clarke, J.; Panwar, B.; Madrigal, A.; Singh, D.; Gujar, R.; Wood, O.; Chee, S.J.; Eschweiler, S.; King, E.V.; Awad, A.S.; et al. Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer. *J. Exp. Med.* 2019. [CrossRef]

20. Duhem, T.; Duhem, R.; Montler, R.; Moses, J.; Moudgil, T.; De Miranda, N.F.; Goodall, C.P.; Blair, T.C.; Fox, B.A.; McDermott, J.E.; et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. *Nat. Commun.* 2018. [CrossRef]

21. Simoni, Y.; Becht, E.; Fehlings, M.; Loh, C.Y.; Koo, S.L.; Teng, K.W.W.; Yeong, J.P.S.; Nahar, R.; Zhang, T.; Kared, H.; et al. Bystander CD8+ T cells are abundant and phenotypically distinct in human tumour infiltrates. *Nature 2018*. [CrossRef]

22. Raczkowski, F.; Rissiek, A.; Ricklefes, I.; Heiss, K.; Schumacher, V.; Wundenberg, K.; Haag, F.; Koch-Nolte, F.; Tolosa, E.; Mittrucker, H.W. Cd39 is upregulated during activation of mouse and human t cells and attenuates the immune response to listeria monocytogenes. *PLoS ONE 2018*. [CrossRef]

23. Canale, F.P.; Ramello, M.C.; Núñez, N.; Furlan, C.L.A.; Bossio, S.N.; Serrán, M.G.; Boari, J.T.; Del Castillo, A.; Ledesma, M.; Sedlik, C.; et al. CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells. *Cancer Res.* 2018. [CrossRef]
24. Takenaka, M.C.; Robson, S.; Quintana, F.J. Regulation of the T Cell Response by CD39. *Trends Immunol.* 2016. [CrossRef]
25. Allard, B.; Longhi, M.S.; Robson, S.C.; Stagg, J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. *Immunol. Rev.* 2017. [CrossRef]
26. Savas, P.; Virassamy, B.; Ye, C.; Salim, A.; Mintoff, C.P.; Caramia, F.; Salgado, R.; Byrne, D.J.; Teo, Z.L.; Dushyanthen, S.; et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. *Nat. Med.* 2018. [CrossRef]
27. Park, S.L.; Buzzai, A.; Rautela, J.; Hor, J.L.; Hochheiser, K.; Efferen, M.; McBain, N.; Wagner, T.; Edwards, J.; McConville, R.; et al. Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin. *Nature* 2019. [CrossRef]
28. Edwards, J.; Wilmott, J.S.; Madore, J.; Gide, T.N.; Quek, C.; Tasker, A.; Ferguson, A.; Chen, J.; Hewavisenti, R.; Hersey, P.; et al. CD103+ tumor-resident CD8+ T cells are associated with improved survival in immunotherapy-naïve melanoma patients and expand significantly during anti-PD-1 treatment. *Clin. Cancer Res.* 2018. [CrossRef]
29. Bhattacharya, A.; Bense, R.D.; Urzúa-Traslawiña, C.G.; de Vries, E.G.E.; van Vugt, M.A.T.M.; Fehrmann, R.S.N. Transcriptional effects of copy number alterations in a large set of human cancers. *Nat. Commun.* 2020. [CrossRef]
30. Riaz, N.; Havel, J.J.; Makarov, V.; Desrichard, A.; Urb, W.J.; Sims, J.S.; Hodi, F.S.; Martin-Algarra, S.; Mandal, R.; Sharifman, W.H.; et al. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. *Cell* 2017. [CrossRef]
31. Willinger, T.; Freeman, T.; Hasegawa, H.; McMichael, A.J.; Callan, M.F.C. Molecular Signatures Distinguish Human Central Memory from Effector Memory CD8 T Cell Subsets. *J. Immunol.* 2005. [CrossRef] [PubMed]
32. Guo, X.; Zhang, Y.; Zheng, L.; Zheng, C.; Song, J.; Zhang, Q.; Kang, B.; Liu, Z.; Jin, L.; Xing, R.; et al. Global characterization of T cells in non-small-cell lung cancer by single-cell sequencing. *Nat. Med.* 2018. [CrossRef]
33. Kim, Y.; Shin, Y.; Kang, G.H. Prognostic significance of CD103 in metastatic melanoma. *Clin. Cancer Res.* 2018. [CrossRef]
34. Szabo, P.A.; Levitin, H.M.; Miron, M.; Snyder, M.E.; Senda, T.; Yuan, J.; Cheng, Y.L.; Bush, E.C.; Dogra, P.; Thapa, P.; et al. Single-cell transcriptomics of human T cells reveals tissue and activation signatures in health and disease. *Nat. Commun.* 2019. [CrossRef] [PubMed]
35. Chen, Y.; Yu, M.; Zheng, Y.; Fu, G.; Xin, G.; Zhu, W.; Luo, L.; Burns, R.; Li, Q.Z.; Dent, A.L.; et al. CXCR5+ follicular helper CD8 T cells control B cell tolerance. *Nat. Commun.* 2019. [CrossRef] [PubMed]
36. Casey, K.A.; Mescher, M.F. IL-21 Promotes Differentiation of Naive CD8 T Cells to a Unique Effector Phenotype. *J. Immunol.* 2007. [CrossRef]
37. Noyv, P.; Huang, X.; Leonard, W.J.; Yang, Y. Intrinsic IL-21 Signaling Is Critical for CD8 T Cell Survival and Memory Formation in Response to Vaccinia Viral Infection. *J. Immunol.* 2011. [CrossRef]
38. Hinrichs, C.S.; Spolski, R.; Paulos, C.M.; Gattinoni, L.; Kerstann, K.W.; Palmer, D.C.; Klebanoff, C.A.; Rosenberg, S.A.; Leonard, W.J.; Restifo, N.P. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. *Blood* 2008. [CrossRef]
39. Xiao, L.; Jia, L.; Bai, L.; He, L.; Yang, B.; Wu, C.; Li, H. Phenotypic and functional characteristics of IL-21-expressing CD8+ T cells in human nasal polyps. *Sci. Rep.* 2016. [CrossRef]
40. Wei, X.X.; Chan, S.; Kwek, S.; Lewis, J.; Diao, V.; Zhang, L.; Cooperberg, M.R.; Ryan, C.J.; Lin, A.M.; Friedlander, T.W.; et al. Systemic GM-CSF recruits effector T cells into the tumor microenvironment in localized prostate cancer. *Cancer Immunol. Res.* 2016. [CrossRef] [PubMed]
41. Chen, J.; López-Moyado, I.F.; Seo, H.; Lio, C.W.J.; Hempleman, L.J.; Sekiya, T.; Yoshimura, A.; Scott-Browne, J.P.; Rao, A. NR4A transcription factors limit CAR T cell function in solid tumours. *Nature* 2019. [CrossRef] [PubMed]
44. Shehata, H.M.; Khan, S.; Chen, E.; Fields, P.E.; Flavell, R.A.; Sanjabi, S. Lack of Sprouty 1 and 2 enhances survival of effector CD8+ T cells and yields more protective memory cells. Proc. Natl. Acad. Sci. USA 2018. [CrossRef]

45. Collins, S.; Waickman, A.; Basson, A.; Kupfer, A.; Licht, J.D.; Horton, M.R.; Powell, J.D. Regulation of CD4+ and CD8+ Effector Responses by Sprouty-1. PLoS ONE 2012. [CrossRef] [PubMed]

46. Orlandini von Niessen, A.G.; Poleganov, M.A.; Rechner, C.; Plaschke, A.; Kranz, L.M.; Fesser, S.; Diken, M.; Löwer, M.; Vallazza, B.; Beissert, T.; et al. Improving mRNA-Based Therapeutic Gene Delivery by Expression-Augmenting 3′ UTRs Identified by Cellular Library Screening. Mol. Ther. 2019. [CrossRef] [PubMed]

47. Ahmed, A.; Thompson, J.; Emiliusen, L.; Murphy, S.; Beauchamp, R.D.; Suzuki, K.; Alemany, R.; Harrington, K.; Vile, R.G. A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat. Biotechnol. 2003. [CrossRef]

48. McNamara, M.A.; Nair, S.K.; Holl, E.K. RNA-Based Vaccines in Cancer Immunotherapy. J. Immunol. Res. 2015. [CrossRef]

49. Van Hoecke, L.; Roose, K. How mRNA therapeutics are entering the monoclonal antibody field. J. Transl. Med. 2019. [CrossRef]

50. Sahin, U.; Türeci, Ö. Personalized vaccines for cancer immunotherapy. Science 2018. [CrossRef]

51. Todd, R.C.; Lippard, S.J. Inhibition of transcription by platinum antitumor compounds. Metalomics 2009. [CrossRef]

52. Brunekreef, K.L.; Paijens, S.T.; Wouters, M.C.A.; Komdeur, F.L.; Eggink, F.A.; Lubbers, J.M.; Workel, H.H.; Van Der Slikke, E.C.; Pröpper, N.E.J.; Leffers, N.; et al. Deep immune profiling of ovarian tumors identifies minimal MHC-I expression after neoadjuvant chemotherapy as negatively associated with T-cell-dependent outcome. Oncoimmunology 2020, 9, 1760705. [CrossRef]

53. Böhm, S.; Braun, M.; Friedrichs, N.; Rudlowski, C.; Keyver-Paik, M.D.; Büttner, R.; et al. Foxp3+ cell infiltration and granzyme B+/Foxp3+ cell ratio are associated with outcome in neoadjuvant chemotherapy-treated ovarian carcinoma. Cancer Immunol. Immunother. 2010. [CrossRef] [PubMed]

54. Khairallah, A.S.; Genestie, C.; Auguste, A.; Leary, A. Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. Int. J. Cancer 2018. [CrossRef] [PubMed]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).